A Phase II, multinational, multicentre, double-blind, randomised, active-controlled, 3-way cross-over study to evaluate the therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in subjects with mild to moderate asthma. [TRECONY]

Mild to moderate asthma

• Change from baseline in FEV1 AUC0-4h on Day 1 • Change from baseline in pre-dose FEV1 on Day 28

Relative and absolute change from pre-dose FEV1 at all post-dose timepoints at each visit, Number and percentage of subjects with a >15% relative decrease from pre-dose in FEV1 at any post-dose timepoint at each visit, Change from pre-dose FEV1 area under the curve from time 0 to 2 h (AUC0-2h) on Day 28, Change from baseline (Day 1) in ACQ-7 scores on Day 28, Average daily use of rescue medication (number of puffs/day), percentage of days without intake of rescue medication and percentage of asthma control days during the TP, Average morning and evening PEF and average daily symptoms during TP

No related papers found yet.